Advancing the Science of DE Technologies
The significant improvements in primary patency and target lesion revascularization rates associated with drug-eluting therapies are impacting the decisions of endovascular specialists. Staying on top of these rapid advancements takes established clinical leadership and a commitment to researching and developing innovative therapies that can make a difference in patients’ lives.
“We’ve now realized that we need a drug effect to avoid intimal hyperplasia….So we're on the right path.”
Baylor St. Luke’s Medical Center | Houston, TX
Proven Polymer-Based Technology with Proven Biocompatibility
The Eluvia Stent uses the same fluoropolymer as the PROMUS™ and XIENCE™ coronary stents which have a proven history of safety in the body.
- Data on file at Boston Scientific. Represents total global sales of the PROMUS (Boston Scientific) and XIENCE (Abbott) stents since 2006.
“It's very, very clear that we're going to need pharmacokinetics to be refined in order to offer improvement in patency, so controlled drug delivery over a longer time frame is clearly a step in the right direction.”
Robert Lookstein, MD
Mount Sinai Medical Center | New York, NY
Antiproliferative Therapies in the SFA
Learn how the biological environment, mechanical challenges and timing of disease progression impact treatment of the SFA and how antiproliferative therapies help reduce the risk of restenosis.